Robbins LLP Reminds Capricor Therapeutics, Inc. Stockholders of the Securities Fraud Class Action After the Company's Stock Fell 64%

Robbins LLP is investigating allegations that Capricor Therapeutics misled investors about the path to FDA approval for Deramiocel. The announcement introduces legal and regulatory risk for Capricor, although the article provides no financial damages, FDA decision, or confirmed findings.